文献速递细菌感染、耐药与抗菌药物

氨曲南/阿维巴坦对2019年欧洲、亚洲和拉丁美洲临床肠杆菌目分离株的体外活性

Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

该研究对来自欧洲、亚太和拉美64个医学中心的8787株临床肠杆菌目分离株进行肉汤微量稀释法药敏试验。结果显示99.9%的分离株对氨曲南/阿维巴坦MIC≤8 mg/L,包括99.7%的碳青霉烯耐药株和99.7%的多药耐药株。结果支持氨曲南/阿维巴坦用于治疗包括产金属β-内酰胺酶菌株在内的肠杆菌目感染。

要点

  • 氨曲南/阿维巴坦对99.9%的肠杆菌目临床分离株MIC≤8 mg/L。
  • 碳青霉烯耐药株和多药耐药株对氨曲南/阿维巴坦的敏感率均为99.7%。
  • 产金属β-内酰胺酶株对氨曲南/阿维巴坦的最高MIC为2 mg/L。

核心结论

  • 氨曲南/阿维巴坦对包括产金属β-内酰胺酶株在内的肠杆菌目临床分离株具有高度体外活性。
  • 结果支持氨曲南/阿维巴坦的临床开发用于治疗肠杆菌目感染。

研究设计与样本

  • 2019年从西欧、东欧、亚太和拉美64个医学中心连续收集8787株临床肠杆菌目分离株。
  • 采用参考肉汤微量稀释法进行药敏试验,按EUCAST标准判读。

主要发现

  • 99.9%的分离株对氨曲南/阿维巴坦MIC≤8 mg/L,MIC50/90为≤0.03/0.12 mg/L。
  • 碳青霉烯耐药株(n=396)中99.7%对氨曲南/阿维巴坦MIC≤8 mg/L,MIC50/90为0.25/0.5 mg/L。
  • 多药耐药株(n=1706)中99.7%对氨曲南/阿维巴坦MIC≤8 mg/L,MIC50/90为0.06/0.5 mg/L。
  • 碳青霉烯耐药率为西欧1.2%、东欧12.9%、亚太5.2%、拉美5.8%,总体4.5%。
  • 碳青霉烯耐药株中90.2%检出碳青霉烯酶,最常见为KPC变异体(35.9%)、NDM(29.0%)和OXA-48(26.8%)。

关键数值与推荐

  • 氨曲南/阿维巴坦对全部分离株MIC≤8 mg/L的抑制率为99.9%。
  • 产金属β-内酰胺酶株(n=110)对氨曲南/阿维巴坦MIC50/90为0.12/0.5 mg/L,最高MIC为2 mg/L。
  • 头孢曲松、美罗培南、左氧氟沙星和阿米卡星的敏感率在西欧最高(分别为80.9%、99.0%、80.7%和97.9%),在东欧最低(分别为52.0%、88.9%、54.1%和84.2%)。

临床怎么用

  • 氨曲南/阿维巴坦可能成为治疗碳青霉烯耐药肠杆菌目感染(包括产金属β-内酰胺酶株)的候选药物。
  • 临床用药需结合当地碳青霉烯耐药率和碳青霉烯酶流行病学特征。

局限性

  • 本研究为体外药敏试验,未评估临床疗效或安全性。
  • 菌株仅来自2019年特定地区的部分医学中心,代表性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aztreonam is a monobactam stable to hydrolysis by metallo-β-lactamases (MBLs) and avibactam is a non-β-lactam β-lactamase inhibitor that effectively inhibits serine carbapenemases (CPs). Aztreonam/avibactam is under clinical development for treatment of serious infections caused by Gram-negative bacteria, including MBL-producers. OBJECTIVES: To evaluate the in vitro activity of aztreonam/avibactam against clinical Enterobacterales isolates. METHODS: 8787 Enterobacterales were collected consecutively from 64 medical centres located in Western Europe (W-EU; n = 4616; 26 centres in 10 nations), Eastern Europe (E-EU; n = 1554; 11 centres in 9 nations), the Asia-Pacific region (APAC; n = 1456; 17 centres in 9 nations), and Latin America (LATAM; n = 1161; 10 centres in 6 nations). Susceptibility tests were performed by reference broth microdilution methods and interpreted according to EUCAST criteria. RESULTS: 99.9% of isolates were inhibited at aztreonam/avibactam MIC of ≤8 mg/L (MIC50/90, ≤0.03/0.12 mg/L), including 99.7% of carbapenem-resistant (CRE; n = 396; MIC50/90, 0.25/0.5 mg/L) and 99.7% of multidrug-resistant isolates (n = 1706; MIC50/90, 0.06/0.5 mg/L). CRE rates were 1.2%, 12.9%, 5.2%, and 5.8% in W-EU, E-EU, APAC, and LATAM, respectively (4.5% overall). A CP was identified in 90.2% of CRE isolates. The most common CPs were variants of KPC (35.9% of CRE), NDM (29.0%), and OXA-48 (26.8%). The highest aztreonam/avibactam MIC value among MBL-producers (n = 110; MIC50/90, 0.12/0.5 mg/L) was 2 mg/L. Susceptibility rates for ceftriaxone, meropenem, levofloxacin, and amikacin were highest in W-EU (80.9%, 99.0%, 80.7% and 97.9%, respectively) and lowest in E-EU (52.0%, 88.9%, 54.1%, and 84.2%, respectively). CONCLUSIONS: Our results support clinical development of aztreonam/avibactam to treat infections caused by Enterobacterales, including MBL-producers.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Sader HS, Carvalhaes CG, Arends SJR, et al. Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. J Antimicrob Chemother. 2021. PMID: 33276387. doi:10.1093/jac/dkaa504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。